Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome

oleh: Amrita Goyal, MD, Damodaran Narayanan, MBBS, PhD, Waihay Wong, MD, PhD, Alvaro C. Laga, MD, Nathan T. Connell, MD, MPH, Susan Y. Ritter, MD, PhD, Gabriela Cobos, MD

Format: Article
Diterbitkan: Elsevier 2022-05-01

Deskripsi

Subjek

autoinflammatory; myelodysplasia; relapsing polychondritis; tocilizumab; UB1A; ubiquitination